Beta Drugs' Q4 FY 2025-26 Quarterly Results

Result Summary

• Beta Drugs Ltd reported a 8.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 0.9%.
• Its expenses for the quarter were up by 7.5% QoQ and 2.1% YoY.
• The net profit increased 6.2% QoQ and increased 0.2% YoY.
• The earnings per share (EPS) of Beta Drugs Ltd stood at 8.93 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Beta Drugs Ltd operates within the pharmaceutical industry, focusing primarily on developing and marketing a variety of drug products. As a company in the healthcare sector, it likely engages in the production and distribution of medications for various conditions, although specific details about its product lineup are not provided here. The company is known for its ongoing commitment to research and development, aiming to deliver innovative healthcare solutions. However, recent major developments or strategic shifts are not specified in the available data.

Revenue

For the fourth quarter of the fiscal year 2026 (Q4FY26), Beta Drugs Ltd reported a total income of ₹96.86 crores. This represents an 8.1% increase from the previous quarter (Q3FY26), where the total income was ₹89.58 crores. Comparatively, the total income in Q4FY26 saw a slight decrease of 0.9% year-over-year (YoY) from ₹97.73 crores in Q4FY25. These changes highlight the fluctuations in revenue performance over the specified periods, reflecting the company's varying income generation capabilities within the market context.

Profitability

In terms of profitability, Beta Drugs Ltd recorded a profit before tax of ₹11.83 crores in Q4FY26, which is a 13.0% increase quarter-over-quarter (QoQ) from ₹10.47 crores in Q3FY26. However, this figure is a 3.3% decrease YoY from the ₹12.23 crores reported in Q4FY25. The tax expense for Q4FY26 amounted to ₹2.78 crores, marking a significant increase of 42.6% QoQ from ₹1.95 crores in Q3FY26, though it decreased by 13.1% YoY from ₹3.20 crores in Q4FY25. Consequently, the profit after tax in Q4FY26 was ₹9.05 crores, reflecting a 6.2% increase QoQ and a marginal 0.2% increase YoY from ₹8.52 crores and ₹9.03 crores, respectively.

Operating Metrics

The earnings per share (EPS) for Beta Drugs Ltd in Q4FY26 was ₹8.93, which denotes a 6.3% rise from the previous quarter's EPS of ₹8.40. There is no available year-over-year comparison for EPS, as the value for Q4FY25 is listed as ₹0.00, which may suggest a data anomaly or a reporting discrepancy for that period. Total expenses for Q4FY26 stood at ₹85.03 crores, up by 7.5% QoQ from ₹79.10 crores in Q3FY26, and a 2.1% increase YoY from ₹83.28 crores in Q4FY25. These metrics provide insight into the company's cost management and operational efficiency over the reported periods.